Stocks and Investing Stocks and Investing
Wed, April 24, 2024
Tue, April 23, 2024

David Nierengarten Reiterated (BEAM) at Buy and Held Target at $57 on, Apr 23rd, 2024


Published on 2024-10-28 10:34:48 - WOPRAI, David Nierengarten
  Print publication without navigation


David Nierengarten of Wedbush, Reiterated "Beam Therapeutics Inc." (BEAM) at Buy and Held Target at $57 on, Apr 23rd, 2024.

David has made no other calls on BEAM in the last 4 months.



There are 4 other peers that have a rating on BEAM. Out of the 4 peers that are also analyzing BEAM, 2 agree with David's Rating of Hold. Following are those relevant analyst calls for the last 4 months


  • Luca Issi of "RBC Capital" Maintained at Hold with Increased Target to $35 on, Wednesday, February 28th, 2024
  • Gena Wang of "Barclays" Maintained at Hold with Increased Target to $42 on, Wednesday, February 28th, 2024


These are the ratings of the 2 analyists that currently disagree with David


  • Kostas Biliouris of "BMO Capital" Maintained at Buy and Held Target at $57 on, Wednesday, March 27th, 2024
  • Eric Joseph of "JP Morgan" Upgraded from Hold to Buy and Increased Target to $40 on, Monday, January 29th, 2024

Contributing Sources